124 related articles for article (PubMed ID: 21666497)
1. Moderate environmental enrichment mitigates tauopathy in a neurofibrillary tangle mouse model.
Lahiani-Cohen I; Lourbopoulos A; Haber E; Rozenstein-Tsalkovich L; Abramsky O; Grigoriadis N; Rosenmann H
J Neuropathol Exp Neurol; 2011 Jul; 70(7):610-21. PubMed ID: 21666497
[TBL] [Abstract][Full Text] [Related]
2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
3. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Boimel M; Grigoriadis N; Lourbopoulos A; Touloumi O; Rosenmann D; Abramsky O; Rosenmann H
J Neuropathol Exp Neurol; 2009 Mar; 68(3):314-25. PubMed ID: 19225406
[TBL] [Abstract][Full Text] [Related]
4. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
Köhler C; Bista P; Götz J; Schröder H
Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
[TBL] [Abstract][Full Text] [Related]
6. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH
Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
8. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
9. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.
Fox LM; William CM; Adamowicz DH; Pitstick R; Carlson GA; Spires-Jones TL; Hyman BT
J Neuropathol Exp Neurol; 2011 Jul; 70(7):588-95. PubMed ID: 21666499
[TBL] [Abstract][Full Text] [Related]
10. Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model.
Yoshiyama Y; Uryu K; Higuchi M; Longhi L; Hoover R; Fujimoto S; McIntosh T; Lee VM; Trojanowski JQ
J Neurotrauma; 2005 Oct; 22(10):1134-41. PubMed ID: 16238489
[TBL] [Abstract][Full Text] [Related]
11. Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease.
Rosa E; Mahendram S; Ke YD; Ittner LM; Ginsberg SD; Fahnestock M
Neurobiol Aging; 2016 Dec; 48():135-142. PubMed ID: 27676333
[TBL] [Abstract][Full Text] [Related]
12. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
13. Modulation of tau pathology in tau transgenic models.
Brion JP; Ando K; Heraud C; Leroy K
Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H
Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729
[TBL] [Abstract][Full Text] [Related]
15. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
16. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
17. Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau.
Klein RL; Lin WL; Dickson DW; Lewis J; Hutton M; Duff K; Meyer EM; King MA
Am J Pathol; 2004 Jan; 164(1):347-53. PubMed ID: 14695347
[TBL] [Abstract][Full Text] [Related]
18. Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice.
Morcinek K; Köhler C; Götz J; Schröder H
Brain Res; 2013 Feb; 1497():73-84. PubMed ID: 23261664
[TBL] [Abstract][Full Text] [Related]
19. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
20. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model.
Ando K; Leroy K; Heraud C; Kabova A; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
Biochem Soc Trans; 2010 Aug; 38(4):1001-5. PubMed ID: 20658993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
